Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis

Next Previous
Search
Trial Profile

A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets once daily to patients suffering from birch pollen rhinoconjunctivitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Stallergenes SA

    • Most Recent Events

    • 04 Apr 2012 Official Title amended as reported by European Clinical Trials Database record.
    • 15 Mar 2012 Actual initiation date changed from Oct 2008 to Aug 2008 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Actual end date (Mar 2009) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top